Search for: "K. S. A." Results 141 - 160 of 39,936
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 May 2024, 9:05 pm by renholding
Last February, the European Council and the European Parliament reached a final compromise on an EU Listing Act.[1] The act aims to make listings in the EU – and raising capital through the stock market – more attractive by simplifying and harmonizing the listing rules. [read post]
1 May 2024, 2:56 pm by Yosi Yahoudai
Innovation Park would also include a K-8 school, parks, businesses and 2,500 homes. [read post]
1 May 2024, 12:36 am by Tom Mayo
The New Yorker has posted an excellent essay ("How ECMO is Redefining Death") on the history, current status, and ethical challenges of extracorporeal membrane oxygenation (a/k/a ECMO), an out-of-body device that bypasses the heart and lungs by taking carbon dioxide out of a patient's blood, oxygenating it, and returning the blood to the patient's circulatory system. [read post]
30 Apr 2024, 3:12 pm by Bill Marler
 E. coli O157:H7 is one of thousands of serotypes Escherichia coli.[1] The combination of letters and numbers in the name of the E. coli O157:H7 refers to the specific antigens (proteins which provoke an antibody response) found on the body and tail or flagellum[2] respectively and distinguish it from other types of E. coli.[3] Most serotypes of E. coli are harmless and live as normal flora in the intestines of healthy humans and… [read post]
30 Apr 2024, 3:12 pm by Parks, Chesin & Walbert
This should tell readers that FLSA non-compliance can be a substantial – and often unnecessary – drain on a business’s revenues. [read post]
30 Apr 2024, 3:10 am by Zack Peckham, Health-E Commerce
That’s why it’s essential that employers and benefits professionals don’t overlook the potential of FSAs and HSAs to support both areas of wellbeing for their company and their workforce. [read post]
29 Apr 2024, 10:00 pm
This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally. [read post]
29 Apr 2024, 10:00 pm
This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally. [read post]
29 Apr 2024, 10:00 pm
This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally. [read post]
29 Apr 2024, 10:00 pm
This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally. [read post]
29 Apr 2024, 10:00 pm by Sherica Celine
New and Updated Practical Guidance Content 401(k) and Other Defined Contribution Plan Compliance Resource Kit Form 5500 Annual Reports Executive and Director Perquisites Benchmarking 401(k) Plans Video Cybersecurity Best Practices in Retirement Plans Checklist Retention Bonus and Change in Control Agreement PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB Experience results today with practical guidance, legal research, and data-driven insights—all in one place. [read post]
29 Apr 2024, 10:00 pm
This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally. [read post]
29 Apr 2024, 10:00 pm
This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally. [read post]